Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03525977 Completed - Clinical trials for Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)

Impact of Fascia Iliaca Block in Hip Fracture Patients

Start date: February 20, 2018
Phase: N/A
Study type: Interventional

The study is a prospective randomized examining the impact of fascia iliaca block on perioperative pain control and post operative ambulation in patients with hip fractures.

NCT ID: NCT03525925 Completed - Clinical trials for Metastatic Malignant Solid Neoplasm

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Start date: July 18, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well ibrutinib and nivolumab work in treating participants with solid tumors that have spread to other places in the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib and nivolumab may work better in treating participants with solid tumors.

NCT ID: NCT03525899 Completed - Clinical trials for Proliferative Diabetic Retinopathy

Macular Hole After Diabetic Vitrectomy

Start date: November 1, 2017
Phase:
Study type: Observational

To present the clinical characteristics and rational treatment of macular hole (MH) after the diabetic vitrectomy (DV) in patients with proliferative diabetic retinopathy (PDR).

NCT ID: NCT03525886 Completed - Clinical trials for CAH - Congenital Adrenal Hyperplasia

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

Start date: April 10, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in up to 30 adult female and male subjects (18 to 50 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). The study will include a sequential-cohort design with four NBI-74788 dosing regimens, with each regimen administered for 14 days.

NCT ID: NCT03525860 Completed - Acupuncture Therapy Clinical Trials

Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting

Start date: July 26, 2018
Phase: N/A
Study type: Interventional

A feasibility study on the provision of acupuncture treatment in the hospital to 20 patients who have undergone open heart surgery procedures. The acupuncture treatments may begin as early as postoperative Day 2.

NCT ID: NCT03525704 Completed - Clinical trials for Contact Lens Complication

Evaluation of Contact Lens Saline Solutions With Scleral GP Contact Lens Wearers Experiencing Fogging

Start date: April 9, 2018
Phase: N/A
Study type: Interventional

Evaluation of saline solutions used with scleral rigid gas permeable contact lens wearers experiencing debris in the post lens tear reservoir

NCT ID: NCT03525158 Completed - Clinical trials for Intrusive Memories of Trauma, Symptom of Post Traumatic Stress Disorder (Criterion B1)

A Brief Cognitive Intervention After Intrusive Memories of Trauma With Young Refugees

Start date: June 20, 2017
Phase: N/A
Study type: Interventional

This research study is designed to investigate the use of a simple cognitive task (a memory cue and 10 minute time gap, followed by playing the computer game "Tetris") for decreasing the number of intrusive memories of trauma among young refugees and asylum seekers. The design is a single case experimental AB design with or without optional replication (ABAB). Participants will aim to complete a no-intervention phase ('A': baseline phase) of one week followed by a one-week intervention phase ('B'), including a one-session intervention with a researcher comprising the simple cognitive task, followed by instructions to continue to use the technique self-guided in the subsequent week. Follow ups are conducted after each week to monitor the occurrence of intrusive memories of trauma in a pen-and-paper diary. It is predicted that participants will report fewer intrusive memories during the intervention phase than during the preceding baseline phase.

NCT ID: NCT03525106 Completed - Clinical trials for Hematopoietic Cell Transplantation Recipient

Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers

Start date: May 18, 2018
Phase: N/A
Study type: Interventional

This trial studies a positive psychology intervention designed to improve quality of life in stem cell transplant survivors and their caregivers. Positive psychology (PP) uses systematic exercises (e.g., gratitude letters, acts of kindness) to potentially boost levels of optimism, resilience, and life enjoyment. PP interventions are often enjoyable, easy to understand, and can be delivered via telephone. PP intervention may improve the quality of life of participants who have undergone a stem cell transplant or their caregivers.

NCT ID: NCT03524612 Completed - Clinical trials for Immune Thrombocytopenic Purpura (ITP)

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

TAPER
Start date: November 2, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.

NCT ID: NCT03524326 Completed - Clinical trials for Head and Neck Cancer

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Start date: April 30, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and cSCC.